Add-on treatment brings functional cure to hepatitis B patients
Bepirovirsen benefits 19% of patients in Phase 3 clinical trials
Written by |
Nearly one in five people with chronic hepatitis B who were given add-on treatment with GlaxoSmithKline (GSK)’s bepirovirsen in two global clinical trials achieved a functional cure.
GSK announced earlier this year that the Phase 3 clinical trials B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820) had hit their main goal, showing bepirovirsen outperformed a placebo at promoting a functional cure in people with chronic hepatitis B.
A functional cure is defined as undetectable levels of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) in the blood for at least 24 weeks (about six months) after stopping all treatment.
Now, full results from the trials have been published in The New England Journal of Medicine, in the study “Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection,” and presented at the European Association for the Study of the Liver Congress, held May 27-30 in Barcelona.
Based on positive data from these trials, GSK has filed applications seeking approval of bepirovirsen in the U.S., Europe, Canada, China, and Japan. The U.S. Food and Drug Administration (FDA) is expected to make a decision by Oct. 26.
“CHB [Chronic hepatitis B] affects over 240 million people worldwide and accounts for over half of global liver cancer cases,” Tony Wood, PhD, GSK’s chief scientific officer, said in a company press release. “For the first time, bepirovirsen offers the possibility of significantly better functional cure rates than the current standard of care, and the potential to reduce the risk of long-term liver complications, including cancer.”
Hepatitis B is a viral infection that affects the liver. Standard treatments, including nucleos(t)ide analogs (NAs), can help control HBV, but patients usually have to keep taking these treatments for life to prevent the infection from worsening. Rates of functional cure are reported in fewer than 1% of cases, according to GSK.
“Today’s standard of care for CHB imposes a heavy burden on patients and healthcare systems, and rarely delivers a functional cure,” said Jinlin Hou, MD, the study’s first author and a professor at Guangdong Institute of Hepatology in China.
Bepirovirsen, being developed in partnership with Ionis Pharmaceuticals, comprises a small piece of genetic material designed to target HBV genetic material for destruction. The aim is to suppress viral replication and production of viral proteins, potentially helping the immune system regain control of the infection and increase chances of a functional cure.
The Phase 3 B-Well studies enrolled nearly 2,000 people with chronic hepatitis B who had blood levels of the viral protein HBsAg between 100 and 3,000 international units per milliliter (IU/mL).
Participants were randomly assigned to receive an under-the-skin injection of either bepirovirsen or a placebo once a week for about six months, in addition to their standard-of-care NAs.
The studies’ main goal was to see how many participants achieved a functional cure after about 1.5 years of follow-up. Pooled data showed that, across both studies, 233 (19%) of 1,220 of the patients given bepirovirsen achieved a functional cure. In contrast, none of the 614 participants on the placebo attained that outcome.
Even higher rates of functional cure, at 26%, were observed in participants with HBsAg levels of 1,000 IU/mL or lower — a subgroup that “represents approximately 45% of diagnosed CHB cases globally,” the company said. This meant the trial met one of its key secondary goals.
Among patients with HBsAg levels greater than 1,000 IU/mL, between 5% and 10% of those treated with bepirovirsen across the two trials achieved a functional cure.
Bepirovirsen also outperformed the placebo on two other key secondary measures that evaluated the proportion of patients showing sustained decreases in blood levels of HBV DNA below the limit of detection after discontinuation of all treatments. This rate was 23% for all bepirovirsen-treated patients and 31% for those showing HBsAg levels up to 1,000 IU/mL. No participant given the placebo met these outcomes.
“With recent guidelines now prioritising functional cure, these new data could represent an important advance,” Hou said. “Combined with improved testing and diagnosis, this innovation has the potential to improve the lives of millions living with CHB.”
Pooled rates of adverse events were higher in the bepirovirsen groups than in the placebo groups (91% vs. 73%), as were those of severe adverse events (7% vs. 4%). The most commonly reported adverse events among participants treated with bepirovirsen were injection side reactions. Most of these events were nonserious and were managed with monitoring and pausing treatment where necessary.
Adverse events led to treatment discontinuation in 3% of participants. Two patients given bepirovirsen died during the study, but both deaths were judged to be unrelated to the treatment.
Yi Rang Kim
Dear , We respect your input regarding research and collaboration.
HBV + HIV antigen-removing mRNA injectable vaccine to be manufactured in your country.
Development of mRNA vaccine immunomaterials for the world's first eradication of HBV + HIV antigens.
Guide to edible mRNA vaccines for the precise removal of infection antigens.
A thorough response to animal viral antigens transmitted to humans is essential for national disease control.
Research on eliminating human and animal viral antigens using chemicals is a waste of time.
Efforts to eliminate viral infection antigens in humans and animals result in the loss of immune cells due to the constant battle between the antigenic virus and the individual's immune cells.
The decisive factor in curing human and animal viral antigen infections lies solely in the activation of autoimmune cells.
We must not forget the fact that no chemical method on Earth can restore or maintain human and animal immune cells to normal levels.
When humans and animals are infected with viruses, the individual's own immune cells are lost, making it difficult to maintain them.
Edible vaccines demonstrate excellent therapeutic effects in eradicating infectious viruses when ingested orally by infected humans and animals.
The role of mRNA edible vaccines is to completely kill the infected virus on immune cells, and through their antigen-eliminating function, they help the individual's immune cells recover and maintain health.
There is a single substance that eliminates both Hepatitis B virus (HBV) and HIV antigens.
Proposal for joint research with your company for the development of a safe and effective HBV vaccine.
Our company proposes cooperation with your company to produce a therapeutic vaccine utilizing an antibody platform developed following the world's first production of an edible therapeutic vaccine.
Is your company interested in collaborating with me to manufacture a cure?
By collaborating with your company we can complete the development of an edible therapeutic vaccine for Hepatitis B that can treat anyone.
Neutralizing antibodies ( bNAbs ) for M / XDR - TV , HBV + HIV Co-infection.
Completion of our company's edible vaccines, proposal for therapeutic vaccine manufacturing with your company,
Proposal to sell national priority antibodies and cooperate in treating viral diseases.
Completion of our company's edible vaccines, proposal for therapeutic vaccine manufacturing with your company,
Proposal to sell national priority antibodies and cooperate in treating viral diseases.
Prioritizing the suffering of your people, our company proposes cooperation in the sales of neutralizing antibodies and the treatment of viral diseases.
Please check with your country's medical testing agency's national toxicology test, human toxicity and compatibility test, and your company's standard audit.Prioritizing the suffering of your people, our company proposes cooperation in the sales of neutralizing antibodies and the treatment of viral diseases.
Please check with your country's medical testing agency's national toxicology test, human toxicity and compatibility test, and your company's standard audit.
At your discretion, we can send you edible vaccine samples.After oral intake of the edible vaccine by the patient ( HBV, HIV, HBV + HIV Co - infection ),
HBV - Changes in patient's virus levels before and after intake.
HIV - Changes in patient's immune cell levels before and after intake.
M / XDR - TB 2 Time required depending on viral loads in cases of chronic illness.
In the case of COVID-19, the manufacturing of edible vaccines that block COVID-19 antigenic variants (HCoV-OC43, HCoV-HKU1, HCoV-NL63, HCoV-229E) has been completed.
The replication and multiplication of infectious viruses usually reaches a figure in the neighborhood of 100 to 200 million over 40 years.
The outstanding results confirm that no other material in the world has achieved this process by 1%.The replication and multiplication of infectious viruses usually reaches a figure in the neighborhood of 100 to 200 million over 40 years.
The outstanding results confirm that no other material in the world has achieved this process by 1%.
The replication and proliferation of the infectious virus typically remain at levels around 100 million to 200 million over 40 years.
The exceptionally excellent results confirm that no other substance in the world has ever achieved 1% of this process.
This process will prove the efficacy of the edible vaccine.
We inform you that the edible vaccine can be supplied through manufacturing and production at your home country, a designated location within your country, or at our headquarters.
Removing viral infection antigens from humans and animals results in the loss of immune cells due to the continuous battle between the virus and the individual's immune cells.
Research using chemicals to remove viral antigens from humans and animals is a waste of time.
You must not forget the fact that no chemical method on Earth can restore or maintain the immune cells of humans and animals to normal levels.
When ingested orally by infected humans and animals, the edible vaccine demonstrates excellent therapeutic effects in eradicating infectious viruses.
The path to HBV antigen removal is to completely kill the infected virus by reinforcing lost immune cells and maintaining normal levels,
and to maintain health by restoring the individual's immune cells through the antigen removal function.
God has not yet revealed the dramatic bill for removing viral infection antigens from the unique and inviolable human body and animals, having prepared a decisive move distinct from that of humans. This is the Virus Antigen Elimination Calculation Sheet, an inviolable formula passed down for 3,000 years.
Number of normal immune cells in the human body.
CD - 4+ T lymphocytes and CD - 8+ cells : 500 ~1600 /mm³
Platelet count : 140,000 ~450,000 /mm³
When infected with a virus, countless immune cells are sacrificed, and the loss of immune cells continues during the ceaseless battle.
Actual CD ~4 and CD - 8 levels are 200 ~300 /mm³.
Platelet count : 10,000 ~20,000/mm³
Due to these figures, daily life becomes very difficult.
The only way to replenish immune cells lost in the fight against infectious viruses is to consume edible vaccines based on medicinal plants.
Requests from research institutions studying the clinical results of therapeutic vaccines support the feasibility of developing vaccines using attenuated live immune cells.
Before administering the edible vaccine, viral antigens are eliminated to verify current viral replication and proliferation levels. (1) JPG.
The viral clearance rate indicates the viral antigen clearance rate 3 months after administering the edible vaccine. (2) JPG.
These are the antibody levels after viral antigens have been completely eliminated by administering the edible vaccine orally once daily for 5 months. (3) JPG.
The regeneration and normalization of immune cells necessary for the eradication of infectious viruses is the only food-based treatment that only God can oversee.
This involves eradicating infectious antigens using an orally ingested edible vaccine,
And this is an example of immune cell enhancement under God's control.
The precise mechanism of Hepatitis B treatment.
One may experience various symptoms such as hepatitis, liver cirrhosis, jaundice, cerebral fibrosis, ascites, and pain caused by ruptured varices.
Ingesting edible vaccines leads to the alleviation of severe symptoms and the path to a complete cure.
Among human infectious viral antigens, the Hepatitis B virus (HBV) is the most difficult to treat. (Complete elimination of protein antigens : HBsAg, HBcAg, HBeAg, and complex antigens)
The world's first "natural medicinal plant extracts" provide the foundation for precise "immunological conversion" therapy that eliminates Hepatitis B virus antigens. (Hospital test records)
Test Name-----------------------------Test Result---------------------------Reference Value----------------------------------- Unit
HBsAg ----------------------------------Neg (<0.05) ------------------------------Neg <0.05 --------------------------------------IU/mL
Anti-HBc -------------------------------Pos ----------------------------------------11.64 ------------------------------------------mIU/mL
Anti-HBs ------------------------------- Pos ---------------------------------------- 11.8 ------------------------------------------ mIU/mL
No other country in the world has produced figures like the above, and this is the first global confirmation by this institute.
This plan serves as a guide to the world's valuable medicinal plant resources, providing answers to the mechanisms of viral antigen eradication for human infectious diseases that modern medicine and science have failed to resolve.
The "processable and edible medicinal plants" mentioned here grow naturally in Korea, North Korea, North and South America, Australia, New Zealand, Russia, India, the Middle East, Egypt, Africa, China, Vietnam, Cambodia, and other regions.
These plants grow naturally.
The consumption of edible vaccines does not affect food, tea, contaminated food and medicines, nutritional supplements, natural foods, vitamins, favorite foods, injections, drugs, contaminated air and water, diet, or lifestyle, and they never conflict with one another.
We promote collaboration for the universal application of various formulations, including CAR-T, cell therapy, and mRNA vaccines.
The development of novel mRNA antibodies capable of eradicating unmet viral antigens through collaborative research is a global achievement.
Because mRNA can be synthesized rapidly and in large quantities in a cell-free system through in vitro transcription of DNA templates, the development of therapeutic vaccines is possible in just a few weeks.
Duration of administration for edible vaccine therapeutics for human infection viral antigen elimination:
HBV - For the edible vaccine designed to eradicate high levels of HBV antigens—which have been in existence for years of replication and proliferation—antigens are automatically eliminated within 6 to 8 months of oral intake.
HIV - Through the oral intake of an edible vaccine for 3 to 5 Months periods aimed at recovering human immune cell deficiencies and maintaining normal levels, antigens are automatically eliminated, and the generation of neutralizing antibodies occurs naturally.
M / XDR - TB dual organ disease requires 6 to 12 months depending on viral load.
COVID - 19 - Manufacturing of edible vaccines blocking COVID-19 antigen mutations completed (HCoV-OC43, HCoV-HKU1, HCoV-NL63, and HCoV-229E)
Mechanism of animal viral antigen elimination.
Antibody generation following the isolation of live animals in a sterile room after infection
Airborne viral infections are a common route of infection resulting from the decline in immune cell function.
Complete elimination of viral antigens is possible only through the regeneration of immune cells and the maintenance of normal cell counts.
This naturally leads to the complete disappearance and eradication of antigens that proliferated after infection.
The regeneration and normalization of immune cells necessary for the eradication of infectious viruses is the only food-based treatment that can be overseen solely by God. This involves eradicating infectious antigens using oral vaccines,
And this is a matter of divine intervention.
Immune cells lost in the fight against infectious viruses have no other option but to consume medicinal plant-based edible vaccines.
Consuming medicinal plants is the only eradication therapy for treating airborne viral infections!
Preventing the release and spread of viruses through underground burial—isolating infected individuals in sterile rooms while they survive—and eradicating infectious antigens through the consumption of edible vaccines are the only ways to break the chain of the recurring vicious cycle.
The realistic approach of underground burial of infected animals results in a vicious cycle of perpetual recurrence, which is the global reality today.
The elimination of infected animal viral antigens requires the complete eradication and removal of the infected antigens through the consumption of edible vaccines following the isolation of infected animals in sterile rooms.
Development of oral vaccines for treating human and animal viral infections completed.
Proposal for joint research regarding the development of injectable vaccine treatments.
Collaboration for the universal application of various formulations, including CAR-T, cell therapy, and mRNA vaccines.
The mechanism for treating animal infections involves isolating patients in a sterile room and administering an edible vaccine to induce a cure and antibody production.
The development of novel mRNA antibodies capable of eradicating unmet viral antigens through collaborative research is a global achievement.
Because mRNA can be synthesized rapidly and on a large scale in a cell-free system induced by the in vitro transcription of RNA templates, vaccines can be developed within weeks.
Medicinal plants have no side effects.
Oral vaccines are highly effective for the prevention and treatment of infection.
Our company proposes a joint clinical trial on a novel airborne virus (natural substance) targeting virus-infected animals.
After removing infectious antigens, the antibody cells from the target animals can be widely utilized with global assistance in the production of therapeutic vaccine platforms.
This 100% natural substance has been proven harmless to the human body, even if just a single drop comes into contact with the eyes of manufacturers of edible vaccines made from pure natural ingredients.
Warmest regards,
Yi Rang Kim
Senior Researcher / Representative Staff
Virus Antigen Eradication Research